HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Reinvestment Rate
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Reinvestment Rate of 2.46x as of September 2025, reinvesting ₩4.60 Billion (capex ₩2.26 Billion plus investments ₩2.34 Billion) from operating cash flow of ₩1.86 Billion. See HLB Pharmaceutical Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
HLB Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for HLB Pharmaceutical Co. Ltd across 3 annual periods. For the full cash flow conversion analysis, see 047920 cash flow conversion.
Annual Cash Flow Reinvestment Rate for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for HLB Pharmaceutical Co. Ltd. See HLB Pharmaceutical Co. Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.24x | ₩15.35 Billion | ₩6.84 Billion | ₩3.09 Billion | ▼ -53.0% |
| 2019 | 4.77x | ₩6.46 Billion | ₩1.35 Billion | ₩1.40 Billion | ▲ +95.2% |
| 2014 | 2.44x | ₩3.77 Billion | ₩1.54 Billion | ₩2.26 Billion | — |